Long-term management of sevelamer hydrochloride-induced metabolic acidosis aggravation and hyperkalemia in hemodialysis patients

Renal Failure

Volumn 28, Issue 5, 2006, Pages 411-418

  Sonikian, Macroui ^a   Metaxaki, Polyxeni ^a   Vlassopoulos, Dimosthenis ^a,b   Iliopoulos, Anastasios ^a   Marioli, Stamatia ^a  

^a AMALIA FLEMING GENERAL HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

Dialysate bicarbonate; Hemodialysis; Hyperkalemia; Hyperphosphatemia; Metabolic acidosis; Sevelamer hydrochloride

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; BICARBONATE; CALCIUM; CHOLESTEROL; PARATHYROID HORMONE; PHOSPHATE; POTASSIUM; SEVELAMER; TRIACYLGLYCEROL;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTERIAL PRESSURE; ARTICLE; BICARBONATE BLOOD LEVEL; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSATE; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DOSE RESPONSE; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; HYPERKALEMIA; MALE; METABOLIC ACIDOSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ACIDOSIS; ADULT; AGED; AGED, 80 AND OVER; BICARBONATES; CALCIUM; DIALYSIS SOLUTIONS; FEMALE; HUMANS; HYPERKALEMIA; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; POLYAMINES; POTASSIUM; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 33745901280     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220600599092     Document Type: Article

References (28)

1. National Kidney Foundation. K/DOQI™ clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(Suppl. 3):51-52.
2. Chertow GM, Burke SK, Lazarus JM, et al. Poly [allylamine hydrochloride] (renagel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis. 1997;29(1):66-71.
3. Chertow GM, Burke SK, Dillon MA, Slatopolski EA, for the Renagel® Study Group. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of hemodialysis patients. Nephrol Dial Transplant. 1999;14:2907-2914.
4. Yamada K, Fujimoto S, Nishiura R, et al. Effects of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. J Am Soc Nephrol. 2004;14:168A [abstract].
5. Chertow GM, Burke SK, Raggi P, et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;63:245-252.
6. Gallieni M, Cozzolino M, Brancaccio D. Transient decrease of serum bicarbonate levels with sevelamer hydrochloride as the phosphate binder. Kidney Int. 2000;57(4):1776-1777.
7. Marco MP, Muray S, Betriu A, et al. Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients. Nephron. 2002;92:499-500.
8. Sadec T, Mazouz H, Bahloul H, et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs. calcium carbonate in dialysis patients: an open label, randomized study. Nephrol Dial Transplant. 2003;18:582-589.
9. Sonikian M, Pani I, Iliopoulos A, et al. Metabolic acidosis aggravation and hyperkalemia in hemodialysis patients treated by sevelamer hydrochloride. Renal Failure. 2005;27:143-147.
10. Mitch WE. Metabolic acidosis stimulates protein metabolism in uraemia. Miner Electolyte Metab. 1996;22:62-65.
11. Brezina B, Qunib WY, Ndan CR. Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int. 2004;66(Suppl. 90):39-45.
12. Wrong OM, Harland CE. Sevelamer-induced acidosis. Kidney Int. 2005;67(2):776.
13. Bommer J, Locatelli F, Satayathum S, et al. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44(4):661-671.
14. Lowrie EG, Lew N. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458-482.
15. Lefebvre A, De Vernejoul MC, Queris J, et al. Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int. 1989;36:1112-1118.
16. Williams AJ, Dittmer ID, McArley A, Clarke J. High bicarbonate dialysate in hemodialysis patients: effects on acidosis and nutritional status. Nephrol Dial Transplant. 1997;12:2633-2637.
17. Lin S-H, Lin Y-F, Chin H-M, Wu C-C. Must metabolic acidosis be associated with malnutrition in hemodialysis patients? Nephrol Dial Transplant. 2002;17:2006-2010.
18. Brady JP, Hasbargen JA. Correction of metabolic acidosis and its effect on albumin in chronic hemodialysis patients. Am J Kidney Dis. 1998;31:35-40.
19. Graham KA, Reaich D, Channon SM, et al. Correction of acidosis in CAPD decreases whole body protein degradation. Kidney Int. 1996;49:1396-1400.
20. Movilli E, Zani R, Carli O, et al. Correction of metabolic acidosis increases albumin concentrations and decreases kinetically evaluated protein intake in hemodialysis patients: a prospective study. Nephrol Dial Transplant. 1998;13:1719-1722.
21. Sonikian M, Pani I, Koutala K, et al. Management of Acidosis Aggravation and Hyperkalaemia Associated with Sevelamer Hydrochloride Treatment in Dialysis Patients. Book of Abstracts of the XLIst Congress of the European Renal Association, European Dialysis and Transplant Association. 2004;104, Abstract SP264.
22. Ciampi MA, Reilly RF. Long-term sevelamer use is associated with a higher serum phosphate, higher Ca x P product and lower serum bicarbonate than calcium-containing binders. J Am Soc Nephrol. 2002;13:586A.
23. Heguilen RM, Sciurano C, Bellusci AD, Fried P, et al. The faster potassium-lowering effect of high dialysate bicarbonate concentrations in chronic hemodialysis patients. Nephrol Dial Transplant. 2005;20:591-597.
24. Nolan CR. Phosphate binder therapy for attainment of K/DOQI™ bone metabolism guidelines. Kidney Int. 2005;68(Suppl. 96):7-14.
25. Uribarri J, Levin NW, Delmez J, et al. Association of acidosis and nutritional parameters in hemodialysis patients. Am J Kidney Dis. 1999;34:493-499.
26. Mehrotra R, Kopple JD, Wolfson M. Metabolic acidosis in maintenance dialysis patients: clinical considerations. Kidney Int. 2003;64(Suppl. 88):13-25.
27. Busevelamerinski DA. Net calcium efflux from live bone during chronic metabolic, but not respiratory, acidosis. Am J Physiol. 1989;256:F836-F842.
28. Graham KA, Hoenich NA, Tarbit M, et al. Correction of acidosis in hemodialysis patients increases the sensitivity of the parathyroid glands to calcium. J Am Soc Nephrol. 1997;8:627-632.